IL4I1 inhibitors and methods of use
AssigneeMerck Sharp & Dohme Corp.
InventorsBrandon D. Cash, Wenlang Fu, George Madalin Giambasu, Andrew M. Haidle, Brett A. Hopkins, Matthew A. Larsen, Charles A. Lesburg, Ping Liu, Meredeth A. Mcgowan, Qinglin Pu, Sulagna Sanyal, Phieng Siliphaivanh, Catherine M. White, Xin Yan
Life of this patent
Estimating the term…
Abstract
Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.
Claims25
A compound, or a pharmaceutically acceptable salt thereof, having the Formula Ia
- wherein,
- A is aryl;
- L is a straight or branched (C1-C5) alkylenyl, wherein one or more —CH2— groups in L are optionally and independently replaced with a moiety selected from the group consisting of O, and NH;
- each occurrence of R1 is independently halogen, C1-C6alkyl, or cycloheteroalkyl;
- each occurrence of R2 is independently
- R3 is hydrogen, C1-C6alkyl or haloC1-C6alkyl;
- m is 0, 1 or 2;
- and
- n is 1, 2 or 3.
A compound having the following structure
A compound having the following structure
- or a pharmaceutically acceptable salt thereof.
A compound having the following structure
A compound having the following structure
- or a pharmaceutically acceptable salt thereof.
A compound having the following structure
A compound having the following structure
- or a pharmaceutically acceptable salt thereof.
A compound selected from:
Dependencies are inferred from the claim text.